PDF herunterladen
CC BY 4.0 · TH Open 2018; 02(01): e1-e7
DOI: 10.1055/s-0037-1615251
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent

Marjolein P. A. Brekelmans
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Harry R. Büller
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Michele F. Mercuri
2   Clinical Development, Daiichi Sankyo Pharma Development, Edison, New Jersey, United States
,
Walter Ageno
3   Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
,
Cathy Z. Chen
4   Global Medical Affairs, Daiichi Sankyo Inc., Parsippany, New Jersey, United States
,
Alexander T. Cohen
5   Department of Haematological Medicine, Guy's and St Thomas' Hospitals, King's College London, London, United Kingdom
,
Nick van Es
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Michael A. Grosso
2   Clinical Development, Daiichi Sankyo Pharma Development, Edison, New Jersey, United States
,
Andria P. Medina
6   Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
,
Gary Raskob
7   College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
,
Annelise Segers
8   Itreas BV, Amsterdam, The Netherlands
,
Thomas Vanassche
9   Vascular Medicine and Haemostasis, University of Leuven, Leuven, Belgium
,
Peter Verhamme
9   Vascular Medicine and Haemostasis, University of Leuven, Leuven, Belgium
,
Philip S. Wells
10   Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada
,
George Zhang
2   Clinical Development, Daiichi Sankyo Pharma Development, Edison, New Jersey, United States
,
Jeffrey I. Weitz
11   Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

29. Juni 2017

13. November 2017

Publikationsdatum:
08. Januar 2018 (online)

   Lizenzen und Reprints

Abstract

Pulmonary embolism (PE) studies used direct oral anticoagulants (DOACs) with or without initial heparin. We aimed to (1) evaluate if PE patients benefit from initial heparin; (2) describe patient characteristics in the DOAC studies; and (3) investigate whether the anatomical extent of PE correlates with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, cause of PE, and recurrence rate. Our methods were (1) an indirect meta-analysis comparing the recurrence risk in DOAC-treated patients with or without initial heparin to those patients given heparin/vitamin K antagonist (VKA). (2) To compare the PE studies, information was extracted on baseline characteristics including anatomical extent. (3) The Hokusai-VTE study was used to correlate anatomical extent of PE with NT-proBNP levels, causes of PE, and recurrent venous thromboembolism (VTE). The meta-analysis included 11,539 PE patients. The relative risk of recurrent VTE with DOACs versus heparin/VKAs was 0.8 (95% confidence interval [CI]: 0.6–1.1) with heparin lead-in and 1.1 (95% CI: 0.8–1.5) without heparin. In the DOAC studies, the proportion of patients with extensive PE varied from 24 to 47%. In Hokusai-VTE, NT-proBNP was elevated in 4% of patients with limited and in over 60% of patients with extensive disease. Cause of PE and anatomical extent were not related. Recurrence rates increased from 1.6% with limited to 3.2% with extensive disease in heparin/edoxaban-treated patients, and from 2.4 to 3.9% in heparin/warfarin recipients. In conclusion, indirect evidence suggests a heparin lead-in before DOACs may be advantageous in PE. Anatomical extent was related to elevated NT-proBNP and outcome, but not to PE cause.

Keywords

pulmonary embolism - venous thromboembolism - right ventricular dysfunction - oral anticoagulants - anatomical extent

Authors' Contributions

M.P.A.B., H.R.B., M.F.M., and J.I.W. were responsible for conception and design or analysis and interpretation of data, or both. All authors had full access to the data and contributed to drafting of the manuscript or revising it critically for important intellectual content and provided final approval of the manuscript submitted.


Funding

This study was performed without financial support. Four authors are employees of the sponsor of the original Hokusai-VTE study, Daiichi Sankyo, who provided data from the Hokusai-VTE study without restrictions.


 

  • References

  • 1 Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014; 124 (07) 1020-1028
    CrossrefPubMedGoogle Scholar
  • 2 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedGoogle Scholar
  • 3 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 4 Schulman S, Kakkar AK, Goldhaber SZ. , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedGoogle Scholar
  • 5 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 6 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 7 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 8 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 9 Rudd KM, Phillips EL. New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. Thrombosis 2013; 2013: 973710
    PubMedGoogle Scholar
  • 10 Gouin B, Blondon M, Jiménez D. , et al; RIETE investigators. Clinical prognosis of nonmassive central and noncentral pulmonary embolism: a registry-based cohort study. Chest 2017; 151 (04) 829-837
    CrossrefPubMedGoogle Scholar
  • 11 Trujillo-Santos J, Di Micco P, Dentali F. , et al; RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 2017; 117 (02) 382-389
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 12 Raskob G, Büller H, Prins M. , et al; Hokusai-VTE Investigators. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost 2013; 11 (07) 1287-1294
    CrossrefPubMedGoogle Scholar
  • 13 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    CrossrefPubMedGoogle Scholar
  • 14 Goldhaber SZ, Schellong S, Kakkar A. , et al. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thromb Haemost 2016; 116 (04) 714-721
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178 (04) 425-430
    CrossrefPubMedGoogle Scholar
  • 16 Konstantinides SV, Torbicki A, Agnelli G. , et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35 (43) 3033-3069 , 3069a–3069k
    CrossrefPubMedGoogle Scholar
  • 17 Lankeit M, Jiménez D, Kostrubiec M. , et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43 (06) 1669-1677
    CrossrefPubMedGoogle Scholar
  • 18 Jiménez D, Kopecna D, Tapson V. , et al; On Behalf Of The Protect Investigators. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2014; 189 (06) 718-726
    CrossrefPubMedGoogle Scholar
  • 19 Sanchez O, Trinquart L, Caille V. , et al. Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. Am J Respir Crit Care Med 2010; 181 (02) 168-173
    CrossrefPubMedGoogle Scholar
  • 20 Brekelmans MP, Ageno W, Beenen LF. , et al. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016; 3 (09) e437-e445
    PubMedGoogle Scholar
  • 21 Ribeiro A, Juhlin-Dannfelt A, Brodin LA, Holmgren A, Jorfeldt L. Pulmonary embolism: relation between the degree of right ventricle overload and the extent of perfusion defects. Am Heart J 1998; 135 (5, Pt 1): 868-874
    CrossrefPubMedGoogle Scholar
  • 22 Wong LF, Akram AR, McGurk S, Van Beek EJ, Reid JH, Murchison JT. Thrombus load and acute right ventricular failure in pulmonary embolism: correlation and demonstration of a “tipping point” on CT pulmonary angiography. Br J Radiol 2012; 85 (1019): 1471-1476
    CrossrefPubMedGoogle Scholar